Cancer "Stem Cell" Co. Raises $93 Million

OncoMed Pharmaceuticals, a Redwood City, Calif.-based cancer “stem cell” company, has raised $93 million in additional Series B funding. Nomura Phase4 Ventures led the new tranche, and was joined by return backers US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners. The Series B round now stands at $154 million, while the company also has a strategic partnership with GlaxoSmithKline that could ultimately be worth up to $1.4 billion.

North AmericaUSBriefs